경보제약

214390KOSPI

58.3 / 100

Reference Date: 2026-09-08

Financial Score20.5 / 40

News Sentiment19.8 / 25

Momentum11.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 5.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongbo Pharm, established in 1987, is a specialty pharmaceutical company specializing in raw material drugs, selling cardiovascular medications, inhalation anesthetics, and general pharmaceuticals. With raw material pharmaceuticals revenue at 137.3 billion KRW and finished pharmaceuticals at 96.8 billion KRW in 2024, the company is preparing to enter the global ADC CDMO market through self-developed technology. It also expands into medical devices and animal health sectors.

Number of Employees

571people

Average Salary

75.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

688.75Industry Average 15.000.0Point

45.9x industry avg (risky)

PBR

0.90Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

0.13Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

18.22Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 1Negative 0Average Sentiment Score 79.2

Positive
국민성장펀드 '항체-약물접합체' 또 베팅…생산 인프라 키운다
경보제약에 대한 정부 지원으로 ADC 생산 인프라 강화, 기업 성장 기대.
Positive
국민성장펀드 주목한 'ADC'…리가켐, R&D 집중 투자로 기술 가치 ...
국민성장펀드의 ADC 투자로 리가켐바이오의 기술 개발에 긍정적 영향 예상.
Positive
국민성장펀드, 경보제약에 200억 투자
경보제약에 대한 국민성장펀드의 200억 투자로 ADC 생산설비 신설 지원이 승인되어 바이오 분야 투자 확대에 기여.

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 5,510Won52-week high 8,55052-week low 4,945

1-month return4.0Point

1m +5.15% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 1Negative 1

Negative[기재정정]주요사항보고서(영업정지)2026-08-31
Neutral반기보고서 (2026.06)2026-08-14